KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) Return on Equity (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Return on Equity for 16 consecutive years, with 0.38% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity rose 93.0% to 0.38% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.38%, a 93.0% increase, with the full-year FY2025 number at 0.4%, up 148.0% from a year prior.
  • Return on Equity was 0.38% for Q4 2025 at Bristol Myers Squibb, down from 0.64% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 47.58% in Q3 2023 to a low of 35.06% in Q1 2024.
  • A 5-year average of 5.59% and a median of 0.02% in 2022 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: skyrocketed 4739bps in 2023, then plummeted -4857bps in 2024.
  • Bristol Myers Squibb's Return on Equity stood at 11.72% in 2021, then skyrocketed by 117bps to 2.0% in 2022, then skyrocketed by 1275bps to 27.53% in 2023, then crashed by -102bps to 0.55% in 2024, then skyrocketed by 169bps to 0.38% in 2025.
  • Per Business Quant, the three most recent readings for BMY's Return on Equity are 0.38% (Q4 2025), 0.64% (Q3 2025), and 28.87% (Q2 2025).